Ledipasvir/sofosbuvir (Harvoni®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000973
English
Authors' recommendations:
Ledipasvir/sofosbuvir (Harvoni®) is recommended as an option for restricted use within NHS Wales for the treatment of chronic hepatitis C in adults with hepatitis C virus genotype 1 and 4 without cirrhosis or with compensated cirrhosis for up to 12 weeks. Ledipasvir/sofosbuvir (Harvoni®) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances. Key factor(s) influencing the recommendation: The cost effectiveness data presented in the submission were insufficient for AWMSG to recommend use beyond 12 weeks. No economic data were provided for genotype 1 or 4 patients with decompensated cirrhosis or who are pre-/post liver transplant. Similarly, no economic data were provided for genotype 3 patients with cirrhosis and/or prior treatment failure.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1887
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Anti-Retroviral Agents
- Antiviral Agents
- Benzimidazoles
- Uridine Monophosphate
- Fluorenes
- Hepatitis C, Chronic
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.